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Abstract
Insulin-like growth factor 1 (IGF-1) is a neuroendocrine signaling
hormone that plays a vital role in growth and development, as well as
learning and memory. Inhibition of this hormone results in cognitive
impairments like those seen with age-related decline. While a majority of
research has focused on the role of IGF-1 on neurons, the role of
astrocytes still needs to be explored. Our research investigates how
astrocytes and cognition are affected as a result of direct regulation of
localized IGF-1 production in early development and after puberty.
Preliminary studies in our laboratory established a connection between
IGF-1 and glial fibrillary acidic protein (GFAP), and in this study we
focused on understanding these changes in GFAP expression that
resulted from astrocyte-derived IGF-1 deficiency. We hypothesized that
mice with astrocyte-derived IGF-1 deficiency would have an increased
number of GFAP positive (GFAP+) cells in the hippocampus, which is
associated with cellular stress and cognitive dysfunction. The pre-pubertal
astro-IGF1 deficient mice had no significant differences in behavior
compared to wild-type. When tissue analysis of the post-pubertal astroIGF1 deficient mice was analyzed utilizing GFAP+ astrocytes, there was a
sex and region-specific difference. The value of this research can be
noted in its effort to determine the role astrocytic IGF-1 plays in
development and cognition. By understanding what happens when
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astrocytic IGF-1 is removed, we can have a better understanding of the
role astrocytes play in cognitive dysfunction.
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Background
Insulin-like growth factor 1 (IGF-1) is crucial for many
developmental processes, including learning and memory. IGF-1 is also
known to be an important regulator of adult neurogenesis, suggesting
roles for cellular development into adulthood. IGF-1 is both produced in
the liver and by glial cells and neurons in the brain. Following early
development, IGF-1 decreases in both plasma and the brain with age (14).
As the loss of IGF-1 correlates with age, many have speculated that it may
contribute to age-related changes associated with the central nervous
system’s ability to repair damage (13). IGF-1 also regulates the
development and growth of glial cells found in the brain. For example,
differentiation of neural progenitor cells into oligodendrocytes- the myelin
producing cells- is dependent on IGF-1 signaling. IGF-1 induces
differentiation of uncommitted cells to oligodendrocyte (OL) fate by
activating BMP antagonists like noggin (15). IGF-1 promotes survival of
oligodendrocyte progenitor cells (OPCs) and OLs by activating
downstream PI3 kinase, which then activates the Akt pathways, inhibiting
apoptosis (16). IGF-1 also directly protects the neurons from damage (2).
Moreover, midbrain dopamine neurons also use IGF-1 to synthesize
dopamine and control dopamine neuron firing (5). Dopamine neurons play
a role in motivation, cognition, and regulating motor control. There are
numerous other functional activities of neurons and glia that are regulated
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by IGF-1, indicating the importance of this growth factor on overall brain
function.
The primary source of IGF-1 in the body is hepatocytes of the liver, which
produce and release IGF-1 into circulation. Over 70% of IGF-1 in the brain
is derived from the liver (17). In the central nervous system neurons,
microglia, and astrocytes produce IGF-1 locally. Microglia are significant
producers of IGF-1, and this is upregulated during the neuroinflammatory
response in proliferating microglia (1). In fact, localized production of IGF1 from microglia is known to protect neurons from inflammatory damage.
We are particularly interested in the effects of IGF-1 produced within
astrocytes, as little is known about the impact of astrocytic-derived IGF-1.
Astrocytes, a multifaceted glial cell, plays many roles in the functioning of
the brain. They guide neuron placement during development, help transfer
nutrients from the blood to the neurons, repair brain injury via neural
scars, degrade neurotransmitters like GABA and glutamate, and
communicate with neurons and other glial cells (18). IGF-1 exerts
neuroprotective mechanisms that are controlled in part by astrocytes. The
release of astrocyte-derived IGF-1 can protect neurons against oxidative
damage (3). Importantly, astrocytes overexpressing IGF-1 were able to
inhibit LPS-mediated expression of proinflammatory cytokines IL6 and IL1β (4). Based on the importance of astrocytes to regulate and produce
IGF-1, our goal is to see how IGF-1 produced by astrocytes affects
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cognitive function and neuroinflammation at various stages of
development and aging.
In order to isolate the effects of astrocyte-derived IGF-1, a genetic
approach that allows for cell-specific targeting of the ligand is required.
Fortunately, cre-lox technology is already available and has been used for
targeting IGF-1 in mice. IGF1f/f mice and inducible astrocyte-specific Cre
expressing mice can be purchased from Jackson Laboratories. Exon 4
which controls expression of the IGF-1 polypeptide is flanked by a LoxP
site. We can then inject tamoxifen at any point, to splice out exon 4 with
the help of Cre-mediated recombination. The astrocyte-specific promoter
for these mice is based on glial fibrillary acidic protein (GFAP). GFAP
functions as a main intermediate filament in mature astrocytes in the
central nervous system. By generating lines of IGFRf/f x iGFAP-Cre mice,
we can examine how the reduction of astrocyte-derived IGF-1 before and
after puberty influences cognition and neuroinflammatory response.
We hypothesized that the loss of astrocyte-derived IGF-1 before and after
puberty would negatively affect cognitive function and increase
neuroinflammatory stress. This hypothesis is based on preliminary studies
in our laboratory indicating that reduced levels of circulating IGF-1
throughout development lead to increased GFAP expression. Since
astrocytes respond to inflammation and injury by upregulating the
production of GFAP, we had predicted that increased stress with reduced
IGF-1 would lead to astrogliosis (10). Together, these studies will highlight
3

the influence of developmental, astrocyte-derived IGF-1 on cognition and
astrogliosis.

Methods
Animals
The in vivo portion of this study consists of two age-equivalent cohorts
with 104 animals total. All procedures were approved by and followed the
guidelines of the Institutional Animal Care and Use Committee (IACUC) at
the University of Mississippi. Transgenic mice possessing loxP sites
flanking exon 4 of the IGF1 gene (Strain #016831) and transgenic mice
with human glial fibrillary acidic protein (GFAP) promoter sequence
directing expression of a Cre-estrogen receptor (Cre-ERT2) fusion protein
(Strain #012849) were purchased from the Jackson Laboratory. They
were bred in-house to utilize tamoxifen-inducible Cre-mediated
recombination for deleting the floxed IGF1 sequence, rendering the IGF-1
polypeptide nonfunctional. Initially, two female homozygous-floxed IGF1
(IGFf/f) mice were crossed with one male hGFAP-Cre/ ERT+ (GCE)
mouse. First generation male GCE/IGFf/+ heterozygotes were bred with
IGF females to produce second generation GCE/IGFf/f(GI) mice. After
this, GI mice generations were bred from GI males with IGFf/f females.
Animals were given different animal ID's, ear punched, and housed in
groups of five or less. Breeding was carried out with animals from different
parents to prevent sibling inbreeding mutations. After each cross,
genotypes of the mice were confirmed using the PCR protocols defined by
4

Jackson Laboratory. Only animals homozygous for the IGF exon 4 loxp
sites and/or expressing the hGFAP-Cre transgene were utilized in this
study. All animals were housed with enriched bedding, and provided
standard rodent chow (5053 Pico Lab, Purina Mills, Richmond, IN) and
water at libitum. Mice were housed in SuperMouse750 (12 x 5.5 in)
ventilated cages on a fixed light/dark (12 h/12 h) cycle.
Cohorts of pre-pubertal and post-pubertal knock-out were induced at 2128 days and 2-3 months, respectively. Recombination was induced by
treating animals with tamoxifen (Sigma, T5648). Both genotypes,
GCE/IGFf/f and IGFf/f were treated with tamoxifen, which only induced
Cre recombinase expression in only the GCE/IGFf/f (KO) mice and not the
IGFf/f (WT) controls. Tamoxifen was diluted in corn oil at a concentration
of 20 mg/ml, solubilized at 37 degrees Celsius overnight, cooled, and
administered i.p. in 100 µl doses for 5 consecutive days with a 25-gauge
needle and 1 ml syringe. Animal housings were discarded and replaced
appropriately following the final day of treatment to reduce biohazard
exposure from tamoxifen. No distress was noted during or following
injections.
Mice in the second cohort were divided into the following 4 treatment
groups prior to behavioral assessment: WT control, WT + LPS, KO
control, and KO + LPS. Injections of saline (0.9% NaCI) or 0.1 mg/kg LPS
(Sigma, L4130) in saline were administered. Initially, four LPS injections
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were planned, however due to high levels of distress following the first and
second injections of LPS remaining treatments were opted out.

Novel Location Novel Object
The novel object test was utilized as a way to test object recognition and
working memory cognitive function (19). The experiment consisted of
three familiarization trials, one novel location task trial, and one novel
object location task trial. Each trial lasted for 5 minutes with a 5-minute
interval between each trial. The familiarization trial was conducted first.
The maze was cleaned with disinfectant (95% ethanol) between each trial
and each animal. For the familiarization trial, two foam block objects were
secured to the bottom of the maze with two-sided tape. The placement
was marked to keep consistency between trials. For the novel location
task trial, the bottom block was rotated 45 degrees counterclockwise
about the top block. This location was also marked to maintain
consistency. The change in spacing creates a novelty stimulus. For the
novel object location task trial, the previously rotated block was replaced
with a differently shaped foam block in the same location. A camera was
placed above the maze, facing down, in order to record the trials. The
amount of time spent around the moved and new objects was recorded for
each trial. Mice have a preference for novel items or stimulus, so a mouse
that recognizes the familiar object will spend its time around the moved or
novel object.
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Elevated Plus Maze
The elevated plus maze was utilized to access the anxiety levels of the
mice (20). The maze had four 61 x 5cm arms in the shape of a plus sign,
with two arms open and two arms closed. The central space was 5 x 5cm.
The maze was two feet from the ground. The maze was sprayed with
disinfectant spray (95% ethanol) and wiped down after each trial. Each
trial was 5 minutes long and the mice were placed in the middle of the
maze. A more anxious mouse would be expected to spend more time in
the closed arms. A camera was placed above the maze, facing down, in
order to record the trials. The amount of time spent in each arm was
recorded. Data from the mice that fell off of the platform were excluded.

Open Field
The open field test was used to analyze the anxiety and exploratory
behavior of mice (21). The maze was a 50cm by 50 cm open arena with
walls 50 cm in height. Mice with more anxiety are more likely to stay
around the periphery of the arena rather than the center. The arena was
cleaned with disinfectant spray (95% ethanol) and wiped down before
each trail. A beam brake system was utilized to track the movement of
each mouse during a 5-minute period. The amount of time spent in the
periphery vs in the center is analyzed.
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Tissue Isolation and Preparation
The brains were removed and cut longitudinally down the middle to
separate the hemispheres. One hemisphere tissue was fixed in 4% PFA
(diluted phosphate buffer) overnight at 4 degrees Celsius. Then the next
day the brain tissue was embedded with 30% sucrose in PB overnight or
until they sunk in the sucrose at 4 degrees Celsius. They were then
removed from the sucrose and rinsed with PBS. The brains were placed in
a mold, flat side down, with a small layer of OCT on the bottom. OCT was
then added to the rest of the mold. The molds were frozen at -80 degrees
Celsius on a metal block. Once ready to slice, the brain molds were
transferred onto a cryosectioning sample holder using OCT to attach. A
Leica cryostat at -20 to -21 degrees Celsius was used to obtain 40-micron
thick slices of the tissue. The slices were placed in 24 well plates with
500µL of cryopreservative (30% sucrose, 30% ethylene glycol, 0.1M
phosphate buffer) in each well.

Immunohistochemistry of Brain Tissue
In order to stain the slices, they were transferred from the cryopreservative
into a 24 well plate containing 500µL of PBS using a small paint brush.
The samples were carefully washed with 500µL of PBS 2 times before
being permeabilized with PBS tween 20 (0.10%) for 20 minutes at room
temperature. Antigen retrieval was required for the samples, so a sodium
citrate buffer was boiled and put into each well. Then the plate was
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incubated at 95 degrees Celsius for 30 minutes. The plate was cooled at
room temperature for 20 minutes. The tissues were then rinsed with PBS
Tween 20 (0.10%) twice for 2 minutes each. The sections were blocked
with PBS 0.5% BSA for 30 minutes at room temperature. Mouse primary
antibody to GFAP (rabbit anti-mouse, abcam, ab7260) was diluted in PBS
0.1% BSA (1:500) before it was used to incubate the sections at 4
degrees Celsius overnight. The sections were rinsed with PBS Tween 20
(0.10%) twice for 2 minutes. They were then incubated with the secondary
antibody (goat, anti-rabbit, Invitrogen, A21245, 1:1000) for two hours at
room temperature. The slices were rinsed with PBS Tween 20 (0.10%)
twice for 2 minutes. Then the slices were incubated with 1:1000 DAPI in
PBS 0.1% BSA for 30 minutes. The tissue was then mounted on the glass
slides using a small paint brush and covered with Prolong Gold Antifade.
Coverslips were placed on each slice, and they were left in a dark place to
dry overnight.

Microscopy
A Nikon Ti2-E inverted fluorescent microscope was used to analyze the
astrocytes. The secondary antibody that was utilized highlighted GFAP
green. Magnification of 20X using a 5x5-7x7 grid was used to obtain the
number of hippocampal astrocytes present. The grid used depended on
the size of the hippocampus. The hippocampal region of each tissue
sample was documented. Each image was reviewed to make sure there
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were no tears, bubbles, or blurry sections in each hippocampal region.
Using the regions of interest software on the Nikon program the cornu
ammonis 1 (CA1), cornu ammonis 2 and 3 (CA2/CA3), and dentate gyrus
(DG) regions were outlined for each image. In each section the astrocytes
were then manually counted and recorded.

Analysis
Block randomization was utilized with random cages of mice receiving a
specific treatment. The statistics were performed and graphs made with
this research using Sigma Plot v14 graphing software. Noldus Ethovision
Software was used to analyze behavioral tests. In order to determine
statistical significance for behavior in the pre-pubertal cohorts, unpaired ttests were run on the collected data to compare treatment groups (WT
and KO). A one-way repeated measure with post-hoc Tukey’s HSD was
performed on behavioral studies with multiple trials. In the post-puberal
cohort, a second factor was added. Therefore, in order to determine
statistical significance for astrocyte count, a two-way ANOVA was run on
the collected data, with treatment and genotype as factors. In all studies,
male and female cohorts were analyzed independently, and alpha was set
at 0.05.
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Results
Pre-pubertal astrocyte-IGF-KO does not alter behavior
The early cohort knock-out mice had their astrocyte-derived IGF-1
deficiency induced before puberty (induced at 21-28 days old). Cognitive
behavior was assessed later in adulthood (5-6 months of age), using a
series of mazes. To assess object recognition and memory cognitive
function novel location and novel object maze was set up according to
figure 1. Exploration time of the novel location vs the non-moving object
was compared for KO vs WT mice for both male and females. No
significant trend was found between the two locations, indicating no
difference in working memory. The exploration time of the novel object vs
the nonmoving object for KO vs WT was also not significantly different
(Figure 2). The discrimination factor for the novel object and novel location
trials was also not significantly different (Figure 3). The pathlength total
(cm) of each trial was plotted for both KO and WT for both males and
females (Figure 4). No significance was noted between WT and KO, with
both groups showing equal declines in exploration as the trials
progressed.
To assess for anxiety the elevated plus maze (EPM) was utilized. If
a mouse spends more time in the closed arm vs the open arm this is
interpreted as anxiety-like behavior. The total exploration (cm) showed no
significant difference between KO and WT mice (Figure 5). For both male
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and female mice, there was no significant difference in time spent in open
arm areas and closed arm areas between KO and WT mice (Figure 6).
To assess for locomotion activity to provide a control to quantify
anxiety-like behavior, the resting time and velocity were analyzed in an
open field arena (Figure 8). There were no significant differences in
resting time or velocity. Mice that spend more time in the periphery than in
the center of the maze are interpreted as having anxiety-like behavior. The
total distance traveled, the time spent in the center, and the time spent in
the periphery were analyzed between KO and WT for females and males
separately (Figure 7). Similar to the elevated plus maze, there was no
significant difference between KO and WT for any value measured.
Post-pubertal astrocyte-IGF-KO alters behavior and inflammatory
response
An independent cohort of astro-IGF1-KO mice were induced postpuberty, to determine whether the reduction in IGF-1 following the pubertal
surge influenced cognition in adulthood (5-6 months of age). Results from
the behavioral studies will be defended by a labmate in the future;
however, the preliminary findings suggested these post-pubertal knock-out
mice had increased levels of anxiety, with no differences in working
memory. To examine changes in astrogliosis and the response to
inflammatory mediators, astrocyte number was then compared between
WT and KO mice, as well as WT and KO mice that received LPS the 2
days before euthanasia.
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The number of astrocytes in the CA1 region, CA2/CA3 region, DG
region, and the total hippocampus were compared. We used a two-way
ANOVA to compare treatment and genotype on astrocyte count.
No effects of LPS treatment or genotype were noted in the number
of astrocytes in the CA1 region in males. A significant main effect of LPS
was noted in the number of astrocytes in male CA2/CA3 region of the
hippocampus (F1,24:7.11, p=0.014). Within the KO mice, LPS significantly
reduced astrocyte count (p=0.019). Within the control group, astrocyte
count was significantly reduced in WT mice (p=0.036). No effects of LPS
treatment or genotype were noted in the number of astrocytes in the DG
region in males. No effects of LPS treatment or genotype were noted in
the number of astrocytes in males in the total hippocampal region (Figure
10).
No effects of LPS treatment or genotype were noted in the number of
astrocytes in female CA1. No effects of LPS treatment or genotype were
noted in the number of astrocytes in female CA2/CA3. A significant main
effect of LPS was noted in the number of astrocytes in the female DG
region of the hippocampus (F1,20:4.51, p=0.049). Within the KO mice,
LPS significantly reduced astrocyte count (p=0.015). No effects of LPS
treatment or genotype were noted in the total number of astrocytes in
females (Figure 12).
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Figure 1: Novel Object Novel Location Maze Set-up

Figure 1: A) Trials F1, F2, and F3 were set up as shown by the figure. B)
Trial NL was set up as shown. C) Trial NO was set up as shown.
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Figure 2: Novel Object Novel Location Exploration Time in
Pre-pubertal astro-IGF1 Deficient Mice

Figure 2: Novel Object/ Novel Location tests were conducted with KO and
WT mice. The total exploration time of the novel object or novel location
for each trial was recorded. In both males (n=16,9) and females(n=6,9),
whether KO or WT, there was no significant difference in exploration time
(p>0.05, t-test).
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Figure 3: Novel Object Novel Location Discrimination
Factor in Pre-pubertal astro-IGF1 Deficient Mice

Figure 3: A discrimination factor between the object in the familiarization
trials and the novel location trial was determined to see if the mice learned
the difference between the novel and familiar stimulus. This was repeated
to determine the discrimination factor between the object in the
familiarization trials and the object in the novel object trial. There was no
significant difference between KO and WT (p>0.05, t-test).
16

Figure 4: Novel Object Novel Location Pathlength in Pre-pubertal
astro-IGF1 Deficient Mice

Figure 4: Novel Object/ Novel Location tests were conducted with KO and
WT mice. The total pathlength for each trial was plotted. In both males
(n=16,9) and females(n=6,9), whether KO or WT, they showed an overall
decreased interest as the trials proceeded.
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Figure 5: Elevated Plus Maze Total Exploration Time in
Pre-pubertal astro-IGF1 Deficient Mice

Figure 5: The total time spent exploring the elevated plus maze regardless
of the region, was recorded. For male (n=12,9) and females (n=4,9) there
was no significant difference in time spent exploring for KO vs WT
(p>0.05, t-test).
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Figure 6: Elevated Plus Maze Time Spent in Open Arm vs
Closed Arm in Pre-pubertal astro-IGF1 Deficient Mice

Figure 6: A mouse with anxiety-like behavior would be expected to spend
more time in the closed arm. Every animal did spend more time in the
closed arm, but there was no significant difference when comparing that
time for KO vs WT.
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Figure 7: Open Field Maze Total Distance Traveled and
Time Spent in Central vs Peripheral Zone in Pre-pubertal
astro-IGF1 Deficient Mice

Figure 7: Mice with anxiety-like behavior would be expected to spend
more time in the periphery than in the center of the maze. The data for the
maze did not produce any significant differences between males (n=16,10)
and females(n=6,9), whether KO or WT mice.
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Figure 8: Open Field Maze Velocity and Resting Time of
Mice in Pre-pubertal astro-IGF1 Deficient Mice

Figure 8: The velocity and resting time of the mice measure the
locomotion activity of the mice. This serves as a control when looking at
the other components that are associated with anxiety. There was no
significant difference between groups for velocity or resting time.
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Figure 9: Grouping of Hippocampal Areas

Figure 9: The hippocampal images were divided into regions A) cornu
ammonis 1 (CA1) B) cornu ammonis 2 and 3 (CA2/CA3) C) dentate gyrus
(DG)
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Figure 10: Astrocyte Count in Male Hippocampus in Postpubertal astro-IGF1 Deficient Mice

Figure 10: A significant main effect of LPS was noted in the number of
astrocytes in male CA2/CA3 region of the hippocampus (F1,24:7.11,
p=0.014). Within the KO mice, LPS significantly reduced astrocyte count
(p=0.019). Within the control group, astrocyte count was significantly
reduced in WT mice (p=0.036).
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Figure 11: Astrocytes in Male CA2/CA3 in Post-pubertal
astro-IGF1 Deficient Mice

Figure 11: Astrocytes in A) WT-C B) KO-C C) KO-LPS
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Figure 12: Astrocyte Count in Female Hippocampus in
Post-pubertal astro-IGF1 Deficient Mice

Figure 12: A significant main effect of LPS was noted in the number of
astrocytes in the female DG region of the hippocampus (F1,20:4.51,
p=0.049). Within the KO mice, LPS significantly reduced astrocyte count
(p=0.015).
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Figure 13: Astrocytes in Female DG in Post-pubertal astroIGF1 Deficient Mice

Figure 13: Astrocytes in A) KO-C B) KO-LPS
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Discussion
Pre-pubertal astrocyte-IGF-KO does not alter behavior
IGF-1 is a critical modulator of depressive-like behavior and
anxiety-like behavior (7,8). Since astrocytes are a major producer of IGF1, we anticipated that removing this source would have an effect on
behavior. We predicted that depressive-like behavior and anxiety-like
behavior would be significantly higher in mice with astrocyte-derived IGF-1
deficiency. When removing astrocytic IGF-1 in early development, we also
expected the mice to show a decreased ability in memory cognitive
function and object recognition. Through behavioral experiments such as
open field, novel object/novel location, and elevated plus maze we
observed no significant difference in the behavior between wild-type and
knock-out mice. Since the liver is a major producer of IGF-1, along with
other glial cells and neurons, this may likely be due to these components
being able to make up for the lost astrocytic IGF-1, and consequently, not
seeing an effect on behavior. Our preliminary studies indicated that IGF-1
gene expression was reduced ~30% in the brain tissue of KO mice,
consistent with other reports suggesting that IGF-1 mRNA is expressed by
other cells within the central nervous system, such as neurons and
microglia. Regardless, pre-pubertal astro-IGF1-KO did not influence
cognitive behaviors at 6 months of age. It is possible that these KO mice
may show differential behaviors later in life, when IGF-1 levels throughout
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the body decline; however further analyses are needed to draw these
conclusions.

Post-pubertal astrocyte-IGF-KO does alter inflammatory astrogliosis
Additional studies in the laboratory suggest that unlike our pre-pubertal
KO mice, reducing IGF-1 production in astrocytes after puberty negatively
influences cognitive behaviors, as multiple measures of anxiety are
increased in KO mice. We set out to examine whether the observed
changes in behavior were associated with changes in astrogliosis. We
expected a rise in GFAP as our lab has previously observed increased
GFAP expression in cognitively impaired mice with systemic IGF-1
deficiency. To best assess for increased GFAP, first counted the number
of GFAP+ cells in the hippocampus. Our results indicate region- and sexspecific differences. Male and female knock-out control had a significantly
higher count of GFAP positive astrocytes than wild-type control in the
CA2/CA3 region of the hippocampus. However, no other regions showed
significant differences between WT and KO in males. It is unclear why this
effect is region specific.
Within females, no difference in astrocyte number was observed
with astro-IGF-KO. A reason for the sex-specific difference in GFAP
expression could be the difference in sex-specific hormones. Studies such
as the one conducted by Santos-Galindo, María et al., observed a sexdependent inflammatory response of astrocytes to LPS. In this study they
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found that female astrocytes have enhanced expression of IP10 while
male astrocytes have increased expression of IL6, TNFα and IL1β. When
females were androgenized, LPS caused expressions similar to that seen
in the males, showing that testosterone could modulate the difference.
Estrogen which is expressed more in females than males has been shown
to activate the IGF-1 pathway (11). This could influence IGF-1 that is
derived from other cells to activate the IGFR1 in astrocytes, explaining
why no difference was seen between female knock-out and wild-type.
To explore whether an inflammatory mediator further enhanced the
astrogliosis response, we administered LPS to a set of animals 2 days
prior to euthanasia. LPS is known to induce a reactive inflammatory
phenotype in astrocytes (8). Due to this we expected astrogliosis to
increase, therefore increasing the amount of GFAP positive astrocytes in
knock-out LPS mice. Our research yielded significant but perplexing
results. Male knock-out control had a significantly higher count of GFAP
positive astrocytes than knock-out LPS in the CA2/CA3 region of the
hippocampus. Female knock-out control had a significantly higher count of
GFAP positive astrocytes than knock-out LPS in the DG region of the
hippocampus. As previously mentioned, we did not expect knock-out
controls to have a higher count of GFAP positive astrocytes than knockout LPS. Some limitations to the study are that we did not account for the
difference in area in the regions when counting the astrocytes. Also, each
sample that was counted was not determined using a stereological
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approach of sequential slices from each brain. This is a limitation to our
research as it could affect the number of astrocytes depending on the
location each sample was taken from.
Future research
There is still a lot of information to be learned about astrocytes and
their effects on the aging brain. Knocking out astrocyte derived IGF-1
before puberty had no significant effect on the behavior of the mice. In the
future it might be beneficial to get the concentration of IGF-1 present in the
serum, or see the effects removing astrocytic-derived IGF-1 has on other
glial cells since it can activate nearby cells in a paracrine manner. It could
be likely that when astrocytic IGF-1 was removed the other producers of
IGF-1 made up for the deficit. Since all mature astrocytes express GFAP,
in the future it might be beneficial to measure the concentrations of GFAP
each astrocyte is expressing as a way of quantifying astrogliosis. In the
study of Tynan et al. 2013, they discovered what they thought to be an
astrocyte number decline due to GFAP testing, was actually just a decline
in the expression of GFAP in the cells. Quantifying the expression of
GFAP may provide more information in the future. In this study, the
removal of astrocytic IGF-1 after puberty yielded a significant increase in
GFAP positive astrocytes but it was sex and region dependent. This
encourages increased exploration of the relation between astrocyticderived IGF-1 and region-specific sex-hormones as we age. By expanding
our knowledge of these influential cells, we could potentially be able to
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create new ways to target and prevent the age-related progression of
neurological degradation by effectively regulating IGF-1.

Note: The completion of pre- and post-pubertal behavior and ex vivo
studies were delayed by COVID-19, which contributed to the separation of
pre-pubertal behavior and post-pubertal tissue analysis.
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